2025 PRESENTER PROFILES
Pregnancy with Type 2 Diabetes—Integrating New Therapies and Technologies
Sunday, June 22, at 8:00 a.m. CT
Room W183 A • McCormick Place Convention Center
Preconception Use of GLP-1 Receptor Agonists—Do the Risks Outweigh the Benefits?
Jacqueline Maya, MD
Physician Investigator,
Mass General Brigham
What is your presentation about?
This presentation will describe the increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists in individuals of childbearing age and the implications of this on the health of the parent and child. There is limited data on the effects that discontinuing treatment for pregnancy has on the parent and offspring. We will review available animal and human data on the impact of preconception use of GLP-1 receptor agonists on pregnancy outcomes.
How do you hope your presentation will impact diabetes research or care?
This presentation aims to contribute to our understanding of GLP-1 receptor agonist use in the periconceptional period in women with diabetes and obesity by describing pregnancy outcomes in mother-child dyads. The purpose of these findings is to guide the decision making process during the preconception period to optimize diabetes and obesity care in pregnancy.
How did you become involved with this area of diabetes research or care?
I am interested in risk factors that contribute to the development of childhood obesity and diabetes, to work toward interventions that decrease the risk of developing diabetes and other long term cardiometabolic complications over the life course. Currently, my research focuses on medication exposures in the birthing individual and the impact these have on pregnancy outcomes and postnatal health of the mother and offspring.
